Fuda Cancer Hospital
Osteosarcoma treatment cost in China typically includes specialized imaging and therapeutic procedures. A PET-CT scan runs from Price on request to Price on request , while limb-salvage options such as resection of bone with implant replacement cost Price on request to Price on request . Total expenses depend on the tumor stage, necessary chemotherapy cycles, and the hospital tier. Patients can see 40-70% savings compared to the US. Top treatment hubs include Guangzhou and Xiamen.
Typical Osteosarcoma Treatment Costs in China
Bookimed Expert Insight: Patients with advanced or late-stage osteosarcoma benefit from minimally invasive therapeutic alternatives. Fuda Cancer Hospital in Guangzhou is the first JCI-accredited cancer center in China. It specializes in cryosurgery and NanoKnife technologies for complex cases. These options provide value for those seeking alternatives to traditional chemotherapy. For precision radiotherapy, Dr. Liu Shi Xin at Xiamen Humanity Hospital offers expert IMRT and SBRT protocols.
| China | Turkey | Austria | |
| Radiation therapy for colorectal cancer | from $11,500 | from $7,000 | from $12,000 |
| Radiation Therapy for Sarcomas | from $10,500 | from $3,250 | from $18,000 |
| Gamma Knife | from $7,800 | from $4,300 | from $32,000 |
| Chemotherapy for breast cancer | from $14,800 | from $1,200 | from $15,000 |
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
China uses a multimodal protocol for osteosarcoma. This strategy combines neoadjuvant chemotherapy, surgical limb-salvage, and postoperative adjuvant chemotherapy. Doctors follow guidelines from the Chinese Society of Clinical Oncology. These protocols prioritize high-dose drug regimens and precision surgery to maximize survival. Successful treatment often involves intensive inpatient care.
Bookimed Expert Insight: Chinese oncology centers often favor a high-intensity inpatient chemotherapy model. Fuda Cancer Hospital stands out by offering over 10 types of minimally invasive therapies. This variety allows doctors to treat advanced cases where standard surgery might be difficult. Their focus on technology like NanoKnife provides options for late-stage patients from over 100 countries.
Patient Consensus: Patients note that treatment is strictly protocol-driven but emphasize seeking second opinions before surgery. They emphasize that access to the best outcomes often requires traveling to specialized high-volume cancer hospitals.
China provides advanced osteosarcoma therapies including targeted agents and cell-based immunotherapies. Specialized centers utilize multi-kinase inhibitors and cryosurgical ablation for metastatic cases. The country hosts 14% of global osteosarcoma clinical trials. Leading facilities integrate genomic profiling with precision oncology protocols for refractory bone tumors.
Bookimed Expert Insight: Clinical data from JCI-accredited facilities like Fuda Cancer Hospital indicates a shift toward multi-modal management. Their approach uses over 10 types of minimally invasive therapies to manage late-stage cancer. We observe that high-volume centers serving over 30,000 international patients often combine immunotherapy with vascular interventional therapy. This strategy aims to improve tumor response when traditional chemotherapy has reached its limits.
Patient Consensus: Patients emphasize that finding an experienced orthopedic oncology team is more important than the hospital's general reputation. Many recommend verifying if a facility performs complex limb-salvage surgery frequently before starting any advanced or alternative therapy plan.
China is home to top-rated oncology centers like Fuda Cancer Hospital and Xiamen Humanity Hospital. These facilities specialize in limb-salvage surgeries and advanced ablation. Many hold JCI accreditation and employ multidisciplinary teams. They treat complex sarcomas using precise radiotherapy and targeted protocols.
Bookimed Expert Insight: Patient volume is a major quality indicator in China. Fuda Cancer Hospital treats over 30,000 patients annually and maintains a 4.6-star rating. This high volume often correlates with better surgical outcomes in rare bone cancers. We recommend choosing centers with dedicated bone tumor departments rather than general clinics.
Patient Consensus: Patients emphasize finding surgeons who perform limb-sparing procedures weekly. They note that having pathology, imaging, and chemotherapy under one roof is essential for success.
Traditional Chinese Medicine (TCM) serves as a supportive adjuvant therapy alongside surgery and multi-agent chemotherapy in China. It optimizes outcomes by mitigating side effects and supporting the immune system. Integrated protocols often include acupuncture and herbal formulations to improve patient quality of life and tolerance for intense oncology regimens.
Bookimed Expert Insight: While major centers like Xiamen Humanity Hospital focus on high-precision radiotherapy, facilities like Fuda Cancer Hospital in Guangzhou demonstrate the regional trend of offering over 10 types of minimally invasive therapies to reduce reliance on aggressive systemic chemotherapy. This shift allows TCM to play a more proactive role in recovery since patients maintain higher baseline strength than those on standard high-dose protocols.
Patient Consensus: Patients note that TCM is most effective for regaining appetite and sleep during recovery. They emphasize that while herbal medicine provides holistic comfort, it must never delay surgery for this aggressive cancer.
International patients can access specialized oncology care in China effectively by utilizing JCI-accredited facilities and dedicated international medical wings. Modern centers provide rapid diagnostic turnaround and advanced therapies. Navigating the system requires pre-arranged medical visas, digital payment setup, and coordination via international patient departments.
Bookimed Expert Insight: Data from Fuda Cancer Hospital shows they have treated over 30,000 patients from 100 countries. This high international volume indicates that choosing major tertiary centers in cities like Guangzhou or Xiamen simplifies the paperwork process. These clinics are better equipped to handle foreign passports and provide the necessary official invitation letters for visa approval.
Patient Consensus: Patients note it is vital to bring all imaging and pathology records in digital form. Having a bilingual advocate or using a dedicated international desk makes navigating daily hospital tasks much smoother.